Alison Handley

Learn More
Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-converting enzyme inhibitor ramipril (RAM) in patients with clinic(More)
A perceptual exploration task involving three horizontal linear arrays of stimuli was administered to 167 children ranging in age from 3 to 7 yr. It was found that the well organized, predominantly right-to-left responses of very young children were eventually replaced by left-to-right patterns. A tachistoscopic test showed that Ss who gave right-to-left(More)
A phase 3, 26-week, open-label, titrate-to-target study (n=418) assessed the safety of azilsartan medoxomil (AZL-M) alone and with chlorthalidone (CLD), followed by a 6-week, double-blind, placebo-controlled reversal phase with change in clinic diastolic blood pressure (DBP) as the primary endpoint. Target blood pressure (BP) was <140/90 mm Hg (<130/80 mm(More)
  • 1